Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial
Results from the interim analysis are consistent with data from the IMbrave150 trial, and further confirm first-line atezolizumab plus bevacizumab as a standard of care for patients with systemic treatment-naive advanced and unresectable HCC.
Authors
- Lorenzo Antonuzzo (ORCID: https://orcid.org/0000-0003-3349-5604)
- Erika Martinelli (ORCID: https://orcid.org/0000-0002-0291-475X)
- Massimo Di Maïo (ORCID: https://orcid.org/0000-0001-8906-3785)
- Tiziana Pressiani (ORCID: https://orcid.org/0000-0001-6919-1536)
- Francesco Tovoli (ORCID: https://orcid.org/0000-0002-8350-1155)
- L. Rimassa
- Giuseppe Cabibbo (ORCID: https://orcid.org/0000-0002-0946-3859)
- Antonio Gasbarrini (ORCID: https://orcid.org/0000-0002-6230-1779)
- Fabio Piscaglia (ORCID: https://orcid.org/0000-0001-8264-1845)
- Giulia Chiara Gazzoli
- C. Astolfi
- F. Bergamo
- C. Celsa
- Donatella Marino (ORCID: https://orcid.org/0000-0001-6565-0870)
- Fortunato Ciardiello (ORCID: https://orcid.org/0000-0002-3369-4841)
- Gianluca Masi (ORCID: https://orcid.org/0000-0001-8329-8989)
- Carlo Garufi
- Bruno Daniele (ORCID: https://orcid.org/0000-0002-2638-3156)
- Francesca Romana Ponziani (ORCID: https://orcid.org/0000-0002-5924-6238)
- Vincenzo Mazzaferro (ORCID: https://orcid.org/0000-0002-4013-8085)
- Massimo Alberto Iavarone (ORCID: https://orcid.org/0000-0003-3493-6504)
- Alberto Ballestrero (ORCID: https://orcid.org/0000-0002-2601-7711)
Institutions
- University of Pisa (IT)
- Humanitas University (IT)
- Agostino Gemelli University Polyclinic (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Ospedale Maggiore (IT)
- Azienda Ospedaliera San Camillo-Forlanini (IT)
- Istituto Oncologico Veneto (IT)
- Roche (Italy) (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Azienda USL di Bologna (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- A. O. Ordine Mauriziano di Torino (IT)
- University of Palermo (AR)
- Ospedale Policlinico San Martino (IT)
- Ospedale D. Cotugno (IT)
- University of the Sacred Heart (JP)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- IRCCS Humanitas Research Hospital (IT)
- University of Florence (IT)
- University of Turin (IT)
- University of Genoa (IT)
- University of Palermo (IT)
- University of Bologna (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1016/j.esmoop.2024.104110
- Citations
- 16
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 21.15
Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Università degli Studi di Cagliari
- Les Laboratories Pierre Fabre
- Incyte
- Eisai
- Università Politecnica delle Marche
- European Society for Medical Oncology
- Siemens Healthineers
- Servier
- Ipsen
- Samsung
- Dipartimento di Medicina e Chirurgia, Università degli Studi di Milano-Bicocca